This technology involves methods to activate natural killer (NK) cells by inhibiting the SHIP1 enzyme, offering new therapeutic approaches to treat cancers and infectious diseases.
Background: Natural killer (NK) cells play a vital role in the body's innate immune defense, targeting and eliminating tumor cells and infected cells. However, their activity can be suppressed in various diseases, limiting their effectiveness. The discovery that SHIP1, an enzyme regulating immune cell function, negatively influences NK cell activation prompted research into inhibiting SHIP1 to restore or enhance NK cell responses. This approach aims to overcome immune suppression in diseases such as cancer and viral infections, where enhancing the body's natural defenses can improve therapeutic outcomes.
Technology Overview: This technology centers on the inhibition of SHIP1 (SH2-domain containing inositol 5'-phosphatase) to activate NK cells broadly and efficiently. By blocking SHIP1 activity, the technology removes an inhibitory checkpoint, allowing NK cells to become more active against disease targets like tumors and infected cells. The patent describes various SHIP1 inhibitors, including small molecule compounds such as 3-alpha-aminocholestane (3AC), alongside genetic methods like RNA interference to reduce SHIP1 expression. These approaches increase NK cell cytotoxicity, which has been validated through experimental studies demonstrating enhanced tumor rejection in animal models. Additionally, the technology covers multiple pharmaceutical formulations suitable for clinical administration, including oral, injectable, and transdermal delivery systems. This flexibility supports different treatment regimens and patient needs. The innovation lies in both the identification of SHIP1 as a key regulator of NK cell activity and the application of its inhibition as a therapeutic strategy, providing a novel means to harness innate immunity in fighting diseases.
https://suny.technologypublisher.com/files/sites/adobestock_463012321.jpeg Photo for reference only, not a depiction of the invention.
Advantages: • Broad activation of NK cells through a targeted mechanism, enhancing the body’s natural immune response. • Effective against multiple disease types, including cancers and viral infections. • Use of both small molecule inhibitors and genetic methods allows for versatile therapeutic strategies. • Validated by experimental data showing increased NK cell activity and tumor rejection in preclinical models. • Multiple pharmaceutical formulations enable adaptable administration routes for patient convenience. • Potential to improve outcomes where current treatments relying on immune activation are limited.
Applications: • Treatment of various cancers by stimulating NK cell-mediated tumor cell destruction. • Therapeutic intervention in viral infections through enhanced innate immune clearance. • Potential use in other diseases where NK cell activity is beneficial to host defense. • Integration into combination therapies to boost immune responses alongside existing treatments. • Development of pharmaceutical products targeting immune modulation for personalized medicine.
Intellectual Property Summary: Issued patent, 10,702,538
Stage of Development: TRL 3 – Experimental proof of concept
Licensing Status: This technology is available for licensing.